Dry Eye (Keratoconjunctivitis Sicca) in Cocker Spaniels: Management Guide

Practical, evidence-based guide to diagnosing and managing keratoconjunctivitis sicca (KCS) in Cocker Spaniels — tests, drug choices, surgery, and daily care.

Quick Overview

• What it is: Keratoconjunctivitis sicca (KCS), or "dry eye," is a common condition in dogs where inadequate tear production leads to chronic corneal and conjunctival inflammation, infection, scarring and vision loss if untreated.
• Who’s at risk: Cocker Spaniels are one of the breeds most predisposed to KCS (immune-mediated and congenital forms are over-represented), especially middle‑aged to older dogs and neutered females.
• Prognosis: With early, appropriate therapy many dogs regain comfortable, functional eyes. Without treatment KCS progresses to corneal ulceration, pigmentation and blindness. Long‑term topical immunomodulation (cyclosporine or tacrolimus) plus supportive care are the mainstays of management.

Pathophysiology — explained simply

Tear film has three layers (lipid, aqueous, mucous) produced by different glands. In KCS the lacrimal glands (main and accessory) make too little aqueous component. Most canine KCS is immune‑mediated destruction of lacrimal tissue (lymphocytic‑plasmacytic inflammation). Less commonly KCS results from congenital anomalies, neurogenic causes, drug effects (e.g., sulfonamides), radiation, or systemic disease. Reduced tears lead to:

• Poor corneal lubrication and epithelial breakdown
• Chronic conjunctival inflammation and mucoid/purulent discharge
• Secondary infection, corneal vascularization, pigmentation and scarring

Cocker Spaniels (American and English) are classically over‑represented among breeds that develop KCS. The condition is frequently immune‑mediated and onset is usually middle‑aged (4–7+ years), though congenital forms can appear earlier. Exact prevalence varies between populations, but multiple veterinary sources and ophthalmology texts list the Cocker Spaniel among the highest‑risk breeds along with the West Highland White Terrier, Shih Tzu, Lhasa Apso and Bulldogs (see Merck Veterinary Manual and ophthalmology references).

Symptoms and grading

Typical clinical signs

• Thick, yellow–green ocular discharge
• Red, inflamed conjunctiva
• Squinting, blinking, rubbing at the eye
• Corneal cloudiness, pigmentation or vascularization in chronic cases
• Reduced vision in severe disease

• Normal: STT > 15 mm/min (many references give normal 15–25 mm/min)
• Mild / early KCS: STT 10–15 mm/min — mild discharge and discomfort
• Moderate KCS: STT 5–10 mm/min — clear signs of conjunctivitis, mucoid discharge
• Severe KCS: STT < 5 mm/min — frequent discharge, corneal ulceration, scarring and pigmentation

1) Physical and ophthalmic exam: Always start with a full ophthalmic exam — eyelid conformation, blink reflex, tear film assessment, and look for corneal ulcers or neoplasia.

2) Schirmer Tear Test (STT I): The single most important quantitative test. Performed using standard strips placed in the lower conjunctival sac for 60 seconds. Interpret using the ranges above. Repeat if results are borderline.

3) Fluorescein staining: Detects corneal ulcers and epithelial defects. Essential to rule out active ulceration before certain therapies.

4) Additional tests as indicated:

• Conjunctival or corneal cytology and culture if heavy purulent discharge or non‑healing ulcers (to identify secondary bacteria).
• Rose bengal or lissamine green may show epithelial compromise but can be irritating.
• Tonometry (intraocular pressure) to rule out glaucoma if indicated.

Treatment options

Goals: Increase tear production, suppress immune‑mediated lacrimal destruction, control infection/inflammation, lubricate the cornea and preserve vision.

Medical therapy — first line

1) Topical immunomodulators (restore tear production and reduce inflammation)

• Cyclosporine ophthalmic ointment 0.2% (commercially available product: Optimmune): Commonly used 1 application to the conjunctival fornix of each affected eye twice daily. Many dogs begin to show improved tear production and decreased discharge within 4–6 weeks; maximal improvement may take 3 months. Long‑term, many dogs require lifelong therapy; some dogs can be tapered to once daily maintenance.
• Tacrolimus (topical ophthalmic preparations): Often used at concentrations of 0.02–0.1% (common starting regimen 0.02–0.03% 1 drop or small ointment dab twice daily). Tacrolimus is more potent than cyclosporine and can be effective in cyclosporine non‑responders. Both drugs are used off‑label in many formulations; preparation and concentration vary, so follow your ophthalmologist/veterinarian’s instructions.

2) Topical antibiotics/anti‑inflammatories

• If secondary bacterial infection is present, use topical broad‑spectrum antibiotics (e.g., chloramphenicol 0.5% drops 1–2 drops q8–12h or as directed) until infection resolves. Avoid prolonged topical corticosteroids unless under specialist supervision because they can worsen corneal ulcers in some cases.

• Artificial tears (drops): Hyaluronic acid (sodium hyaluronate) or carboxymethylcellulose solutions — 1–2 drops QID to hourly depending on severity.
• Gels and ointments for overnight protection (e.g., petrolatum-based ocular ointment) — applied at night and more frequently in severe cases.

• Oral pilocarpine (a parasympathomimetic) can increase tear production in selected neurogenic cases but has systemic side effects (salivation, vomiting, diarrhea) and is used infrequently. Dosage and suitability should be determined by your veterinarian.

1) Parotid duct transposition (PDT)

• Indication: Severe, refractory KCS where medical therapy fails to produce adequate tear film and the eye is at risk for corneal loss of transparency.
• Procedure: The parotid salivary duct is surgically diverted to drain onto the conjunctival fornix to replace aqueous tear film with saliva.
• Benefits: Often restores ocular surface moisture and comfort; many dogs gain functional vision and become comfortable.
• Downsides/complications: Chronic mucoid or serous discharge, saliva has different composition (can cause thick deposits), dental tartar increase on the operated side, need for long‑term oral or topical management, possible stricture or stenosis of the new duct opening. Success rates are variable but many case series report good to excellent improvement in comfort and corneal health in a majority of dogs.

• Temporary measures to conserve tears: small surgical tarsorrhaphy (partial eyelid closure) or punctal occlusion (surgical or plug) may be used palliatively.

• Moisture chambers/goggles: For dogs that tolerate them, moisture‑retaining masks or protective goggles reduce evaporative loss.
• Omega‑3 fatty acid supplementation: May have mild anti‑inflammatory benefit; evidence is limited and it should be adjunctive.

• Expect lifelong management in most immune-mediated KCS cases.
• Re-check schedule: Reassess at 4–6 weeks after starting therapy (to assess STT and corneal healing), then every 3 months for the first year and every 6–12 months thereafter if stable. Frequency increases if signs change.
• Tests at follow‑up: STT, fluorescein stain if corneal disease suspected, ophthalmic exam for conjunctival and corneal health.
• Medication adjustments: Many dogs remain on lifelong cyclosporine or tacrolimus; if a dog responds well a gradual reduction to once daily maintenance may be attempted, but stopping therapy often leads to relapse.
• Manage secondary problems: Treat bacterial overgrowth promptly; address eyelid conformation (entropion/ectropion) surgically if it contributes to irritation.

• With prompt diagnosis and appropriate therapy most dogs regain comfort and maintain usable vision. Many dogs treated with topical cyclosporine or tacrolimus show clinically meaningful improvement.
• Severe, long‑standing KCS with corneal scarring or pigment has a worse visual prognosis.
• Surgical options such as PDT can dramatically improve quality of life when medical therapy fails, but owner acceptance of potential side effects is essential.

• Establish a daily medication schedule and use pill‑box or phone alarms to ensure consistency. Topical immunomodulators require regular dosing for effect.
• Clean discharge daily: Use warmed sterile saline or cooled boiled water and a soft gauze pad to gently remove crusts. Work from the corner outward and use a fresh pad for each eye.
• Use artificial tears liberally: For moderate disease use drops 4–6 times daily; for severe disease use hourly creams/gels and ointment at night.
• Protect from wind and dust: Avoid windy walks, or consider canine goggles (e.g., Doggles®) for sensitive dogs.
• Grooming: Keep hair trimmed away from the eyes to reduce irritation and prevent particulate contamination.
• Emergency plan: Know how to recognize corneal ulcers (sudden squinting, excessive tear, bright fluorescein uptake) and where to take your dog for urgent care.

Seek immediate veterinary care if your Cocker Spaniel has:

• Sudden onset of severe squinting, pawing at the eye, or pain
• New or worsening corneal cloudiness, ulceration or bleeding
• Markedly increased discharge that is thick, green and malodorous
• Sudden vision loss or pupil abnormalities

Key medications and dosing concepts (examples — follow your vet's instructions)

• Cyclosporine ophthalmic ointment 0.2% (Optimmune): typically one application to the conjunctival fornix twice daily; reassess after 4–6 weeks. Some dogs can drop to once daily maintenance.
• Tacrolimus ophthalmic (various compounded concentrations 0.02–0.1%): commonly started as one drop or small ointment dab twice daily; used in cyclosporine non‑responders or severe disease.
• Artificial tears (sodium hyaluronate 0.1–0.3%): 1–2 drops q6–8h for mild disease; increase frequency for moderate–severe disease.
• Topical antibiotic (chloramphenicol 0.5%): 1–2 drops q8–12h when bacterial infection suspected.

Primary citation

• Merck Veterinary Manual: Keratoconjunctivitis Sicca (KCS). https://www.merckvetmanual.com/eye-and-ear/eye/keratoconjunctivitis-sicca-kcs

This guide is for educational purposes. Always consult your veterinarian for diagnosis and treatment.

Frequently Asked Questions